Recent interest in personalized medicine has highlighted the importance of research in ethical, legal, and social issues (ELSI). Issues in ELSI research may be magnified in the rare diseases population (i.e., small numbers of affected individuals, challenges in maintaining confidentiality, and paucity of treatments for diseases where natural history information may be limited). More than other areas of research, potential barriers include the lack of funding opportunities and appropriate review processes for applications to funding agencies. The ELSI Working Group of the International Rare Diseases Research Consortium (IRDiRC) performed an informal survey on ELSI funding initiatives to learn more about different funding mechanisms and to identify potential gaps in funding opportunities. The Working Group discusses these challenges and highlights the role of funding agencies and partners such as patient advocacy groups, specialists in social sciences and humanities, and clinicians to advance ELSI research in rare diseases.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
National Research Council. Mapping and sequencing the human genome. Washington, DC: The National Academies Press; 1988. https://www.nap.edu/read/1097/chapter/1. Accessed 13 Jan 2019.
McEwen JE, Boyer JT, Sun KY, Rothenberg KH, Lockhart NC, Guyer MS. The Ethical, Legal, and Social Implications Program of the National Human Genome Research Institute: reflections on an ongoing experiment. Annu Rev Genomics Hum Genet. 2014;15:481–505.
Meslin EM, Thomson EJ, Boyer JT. The Ethical, Legal, and Social Implications Research Program at the National Human Genome Research Institute. Kennedy Inst Ethics J. 1997;7:291–8.
US Government Publishing Office. Genetic Information Nondiscrimination Act of 2008. 2008. https://www.govinfo.gov/content/pkg/PLAW-110publ233/pdf/PLAW-110publ233.pdf. Accessed 27 Jan 2019.
US Government Publishing Office. Revised Common Rule. 2017. https://www.govinfo.gov/content/pkg/FR-2017-01-19/pdf/2017-01058.pdf. Accessed 27 Jan 2019.
Gainotti S, Mascalzoni D, Bros-Facer V, Petrini C, Floridia G, Roos M, et al. Meeting patients’ right to the correct diagnosis: ongoing international initiatives on undiagnosed rare diseases and ethical and social issues. Int J Environ Res Public Health. 2018;15:10.
McCormack P, Kole A, Gainotti S, Mascalzoni D, Molster C, Lochmüller H, et al. ‘You should at least ask’. The expectations, hopes and fears of rare disease patients on large-scale data and biomaterial sharing for genomics research. Eur J Hum Genet. 2016;24:1403–8.
Bereza E. The use of clinical databases in disease outcomes research: Is the ethics of IRB review keeping up? Mult Scler. 2017;23:1325–7.
Polisena J, Burgess M, Mitton C, Lynd LD. Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey. BMC Health Serv Res. 2017;17:372.
Hallowell N, Parker M, Nellåker C. Big data phenotyping in rare diseases: some ethical issues. Genet Med. 2019;21:272–4.
Parker LS, Sankar PL, Boyer J, Jean McEwen JD, Kaufman D. Normative and conceptual ELSI research: what it is, and why it’s important. Genet Med J Am Coll Med Genet. 2019;21:505–9.
Knoppers BM. Framework for responsible sharing of genomic and health-related data. HUGO J. 2014;8:3.
Mascalzoni D, Dove ES, Rubinstein Y, Dawkins HJ, Kole A, McCormack P, et al. International charter of principles for sharing bio-specimens and data. Eur J Hum Genet. 2015;23:721–8.
Gainotti S, Turner C, Woods S, Kole A, McCormack P, Lochmuller H, et al. Improving the informed consent process in international collaborative rare disease research: effective consent for effective research. Eur J Hum Genet. 2016;24:1248–54.
Schieppati A, Henter J-I, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371:2039–41.
Cannizzo S, Lorenzoni V, Palla I, Pirri S, Trieste L, Triulzi L, et al. Rare diseases under different levels of economic analysis: current activities, challenges and perspectives. RMD Open. 2018;4:e000794.
Lander ES, Baylis F, Zhang F, Charpentier E, Berg P, Bourgain C, et al. Adopt a moratorium on heritable genome editing. Nature. 2019;567:165.
Baker D, Knoppers BM, Phillips M, van Enckevort D, Kaufmann P, Lochmuller H, et al. Privacy-preserving linkage of genomic and clinical data sets. IEEE/ACM Trans Comput Biol Bioinform. 2019;16:1342–8.
Kodra Y, Weinbach J, Posada-de-la-Paz M, Coi A, Lemonnier SL, van Enckevort D, et al. Recommendations for improving the quality of rare disease registries. Int J Environ Res Public Health. 2018;15. https://doi.org/10.3390/ijerph15081644.
Monaco L, Crimi M, Wang CM. The challenge for a European network of biobanks for rare diseases taken up by RD-Connect. Pathobiol J Immunopathol Mol Cell Biol. 2014;81:231–6.
FDA. FDA: Orphan Drug Act. 1983. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm2005643.htm. Accessed 27 Jan 2019.
European Commission. EC: Regulation No 141/2000 of the European Parliament and of the Council on Orphan Medical Products. 2000. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf. Accessed 27 Jan2019.
PMDA. PMDA: The Article 77–2 of the Pharmaceutical Affairs Law. 1985. https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/dl/05.pdf. Accessed 27 Jan 2019.
Gericke CA, Riesberg A, Busse R. Ethical issues in funding orphan drug research and development. J Med Ethics. 2005;31:164–8.
Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? Orphanet J Rare Dis. 2017;12:1.
Heeney C, Hawkins N, de Vries J, Boddington P, Kaye J. Assessing the privacy risks of data sharing in genomics. Public Health Genomics. 2011;14:17–25.
Hardavella G, Bjerg A, Saad N, Jacinto T, Powell P. How to optimise patient and public involvement in your research. Breathe. 2015;11:223–7.
PARADIGM. PARADIGM, patients active in research and dialogues for an improved generation of medicines. 2019. https://imi-paradigm.eu. Accessed 27 Jan 2019.
IRDiRC. International Rare Diseases Research Consortium. IRDiRC. 2019. http://www.irdirc.org/. Accessed 13 Jan 2019.
Dawkins HJS, Draghia-Akli R, Lasko P, Lau LPL, Jonker AH, Cutillo CM, et al. Progress in rare diseases research 2010-6: an IRDiRC perspective. Clin Transl Sci. 2018;11:11–20.
FFRD. Appel à projets de recherche 2018 «Sciences humaines et sociales & maladies rares». https://www.fondation-Mal.Contentuploads2018022018SHSMR.pdf. Accessed 13 Jan 2019.
NIH. PA-17-325: Ethical, Legal, and Social Implications (ELSI) of Genomics Research Project Grant Program (R01). 2017. https://grants.nih.gov/grants/guide/pa-files/pa-17-325.html. Accessed 28 Jan 2019.
Japan Agency for Medical Research and Development. Awarded Projects under the Research and Development Program for Enhancement of Research Integrity. 2016. https://www.amed.go.jp/en/news/program/1001C_00010.html. Accessed 28 Jan 2019.
BMBF-Internetredaktion. Bekanntmachung - BMBF. Bundesminist. Für Bild. Forsch. - BMBF. 2018. https://www.bmbf.de/foerderungen/bekanntmachung-2103.html. Accessed 28 Jan 2019.
Horizon 2020—European Commission. Science with and for Society. Horiz. 2020 - Eur. Comm. 2013. https://ec.europa.eu/programmes/horizon2020/en/h2020-section/science-and-society. Accessed 28 Jan 2019.
NIH. The Health of Sexual and Gender Minority (SGM) Populations (R21 Clinical Trial Optional). 2013. https://grants.nih.gov/grants/guide/pa-files/PA-18-040.html. Accessed 28 Jan 2019.
Berg JS, Agrawal PB, Bailey DB, Beggs AH, Brenner SE, Brower AM, et al. Newborn sequencing in genomic medicine and public health. Pediatrics. 2017;139. https://doi.org/10.1542/peds.2016-2252.
E-Rare. ERA-net for research programmes on rare diseases. 2018. http://www.erare.eu. Accessed 16 Feb 2019.
NIH Administrative Supplement for Research on Bioethical Issues (Admin Supp Clinical Trial Optional) - PA-19-217. 2019. https://grants.nih.gov/grants/guide/pa-Files/PA-19-217.html.
Members and contributors of the IRDiRC ELSI Working group included ALH, HD, RI, DJ, NL and MP. In addition, we would like to thank Domenica Taruscio (ISS, Italy) and Manuel Posada (ISCIII, Spain) for their review and feedback on the manuscript.
The IRDiRC Scientific Secretariat was supported by the European FP7 contract “SUPPORT-IRDiRC”(N° 305207). Daria Julkowska received funding from the European Union’s Horizon 2020 Research and Innovation Program under grant agreement EJP RD N°825575.
Conflict of interest
The authors declare no competing interests. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Human Genome Research Institute, National Institutes of Health, Department of Health and Human Services, or the US Government.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hartman, A.L., Hechtelt Jonker, A., Parisi, M.A. et al. Ethical, legal, and social issues (ELSI) in rare diseases: a landscape analysis from funders. Eur J Hum Genet 28, 174–181 (2020). https://doi.org/10.1038/s41431-019-0513-3
European expert network on rare communicable diseases and other rare diseases linked to mobility and globalisation focused on health care provision (EURaDMoG): a feasibility study
Orphanet Journal of Rare Diseases (2020)
Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response
Immuno-Oncology Technology (2019)